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Identity 
Hugo: AIFM1 
Other names: AIF; PDCD8; MGC111425 
 
Location: Xq25 
Local order: Centromere (59,500 Kbp)- ARHGEF9 - 
(…) - RAB33A - AIFM1 - ELF4 - (…) - IL9R -
telomere (154,914 Kbp). 
 
 
AIF gene structure and known isoforms. Genomic organization of AIF and resulting AIF, AIF-exB, AIFsh, AIFsh2, and AIFsh3 mRNA 
transcripts (schemas in the left). Translation start (ATG, in green) and stop (TGA/TAA, in red) codons are indicated, and the predicted 
protein product is shown at the right. Numbers in AIF designate exons (in mRNA transcripts) and amino acids (in the predicted proteins). 
Mitochondria localization signal (MLS), Pyridoxin-redox (Pyr-Redox), nuclear localization sequence (NLS), and C-terminal domains are 
indicated. I9 (in green) indicates intron 9. The inclusion of the 203-bp exon 9b (lettering in red) produces AIFsh2 and AIFsh3, which 
encodes 324- and 237-amino acid proteins, respectively. AIFsh2 contains the MLS and the Pyr-Redox domain, but lacks the C-terminal 
portion of AIF. AIFsh3 has a similar structure as AIFsh2 with the splicing of exon 2, leading to the loss of MLS. Blue lines indicate the 
splicing of the different isoforms. 
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DNA/RNA 
Note: AIF (Apoptosis-Inducing Factor). Total gene 
size 36.471 Kb with a transcribed region of 2.215 Kb 
which codes for 613 amino acids. To date, five 
isoforms from AIF gene have been described (AIF, 
AIFexB, AIFsh, AIFsh2, and AIFsh3). 
Description 
16 exons spanning 36.471 Kb. 
Transcription 





Figure 1: Schematic model representing the three different AIF forms: precursor, mature, and truncated. AIF is a flavoprotein (with an 
oxidoreductase enzymatic activity) containing a FAD-bipartite domain (yellow, amino-acids 128-262 and 401-480), a NADH-binding motif 
(violet, amino-acids 263-400), and a C-terminal domain (red, amino-acids 481-608) where the proapoptotic activity of the protein resides. 
In addition, it has a Mitochondria Localization Sequence (MLS, in green, amino-acids 1-41) placed in its N-terminal region. Between the 
first-N-terminal FAD motif and the MLS, AIF possesses a potential Transmembrane Domain (TM, in green, amino-acids 67-83). This TM 
is flanked by two peptidase-processing positions: a Mitochondrial Processing Peptidase (MPP)-cleavage site (in blue, amino-acid 54) 
and a calpains- and/or cathepsins-cleavage site (in red, amino-acid 103). Hsp70 (Heat Shock Protein-70) and CypA (Cyclophilin A) bind 
AIF in amino-acids 150-228 and 367-369, respectively. AIF also possesses two DNA-binding sites, which are located in amino-acids 
255-265 and 510-518, respectively. AIF precursor protein has 613 amino-acids. The MPP-mediated cleavage generates the 
mitochondrial mature AIF (amino-acids 55-613). After an apoptotic insult, calpains or cathepsins cleave AIF to produce truncated-AIF 
(tAIF), which is released from mitochondria to cytosol (amino-acids 104-613). 
Figure 2: Ribbon structure of mouse AIF in its mature form (pdb id: 1GV4). As depicted here, three domains are present in the protein. 
The FAD-binding domain and the NAD-binding domain (yellow) are both similar to oxidoreductase domains from members of the 
glutathione reductase family. In contrast, the C-terminal domain (blue) displays a particular folding with a specific insertion, which 
includes residues 580 to 610. This picture also includes the AIF cofactor Flavin Adenine Dinucleotide (FAD; magenta). 
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Protein 
Note: 613 amino acids long protein whose structure 
may be divided into three domains: a FAD-binding 
domain (residues 128-262 and 401-480), a NADH-
binding domain (residues 263-400), and a C-terminal 
domain (residues 481-608). 
Description 
AIF was initially identified as a protein released from 
the mitochondrial intermembrane space during the 
apoptotic process. First studies showed that upon an 
apoptotic stimulus AIF translocates from mitochondria 
to cytosol and further to the nucleus where it triggers 
caspase-independent programmed cell death. AIF, 
expressed as a precursor of 67 kDa, is addressed to 
mitochondria by the two MLS placed within the N-
terminal prodomain of the protein. Once in 
mitochondria, this precursor is processed to a mature 
form of 62 kDa by a first proteolytic cleavage. In this 
configuration, AIF is an inner-membrane-anchored 
protein in which the N-terminus is exposed to the 
mitochondrial matrix and the C-terminal portion to the 
mitochondrial intermembrane space. AIF is here 
required for maintenance or maturation of the 
mitochondrial respiratory chain complex I. After a cell 
death insult, the 62 kDa AIF-mitochondrial form is 
cleaved by activated calpains and/or cathepsins to yield
a soluble proapoptotic protein with an apparent 
molecular weight of 57 kDa tAIF (truncated AIF). tAIF 
is released from mitochondria to cytosol and nucleus to 
generate two typical hallmarks of caspase-independent 
programmed cell death: chromatin condensation and 






AIF has a double life/death function. 
In its vital role, AIF is required to maintain and/or 
organize the mitochondrial respiratory complex I, and 
displays NADH oxidoreductase and peroxide 
scavenging activities. In addition to this vital function, 
AIF has been shown to be implicated in programmed 
cell death (PCD) induction in several experimental 
models (see bibliography section). In the two most 
studied AIF-dependent PCD models, AIF death activity 
is associated with the increase of intracellular Ca2+ 
(e.g., ischemia/reperfusion injury), or relates with 
extensive DNA-damage (e.g., treatment with alkylating 
agents). In the first model, increased intracellular C 2+ 
levels trigger depolarization of mitochondrial 
membrane, subsequent loss of membrane potential, 
generation of reactive oxygen species (ROS), and AIF 
mitochondrial release. In the second model, extensiv  
DNA damage, provoked by high doses of alkylating 
agents such as MNNG or MNU, triggers poly(ADP-
ribose) polymerase-1 (PARP-1) over-activation and 
AIF release from the mitochondrial intermembrane 
space. This cell death pathway sequentially involves 
PARP-1, calpains, Bax, and AIF. 
 
Figure 3: Phylogenetic tree representing the relationship between AIF and other oxidoreductases from different species. Note the 
proximity of the AIF family (red branch) to the NADH-oxidase family from Archaea. The PIR accession codes are enumerated following 
the abbreviation of each specie: AA: Aquifex aeolicus; AC: Acinetobacter calcoaceticus; AF: Archaeoglobus fulgidus; AT: Arabidopsis 
thaliana; BC: Burkholderia cepacia; BS: Bacillus subtilis; CE: Caenorhabditis elegans; DD: Dictyostelium discoideum; DM: Drosophila 
melanogaster; EC: Escherichia coli; HS: Homo sapiens; LS: Lycopersicon esculentum; MJ: Methanocaldococcus jannaschii; MM: Mus 
musculus; MTH: Methanobacterium thermoautotrophicum; N A: Novosphingobium aromaticivorans; PF: Pseudomonas fluorescens; PH: 
Pyrococcus horikoshii; PO: Pseudomonas oleovorans; PP: Pseudomonas putida; PS: Pseudomonas sp.; PSA: Pisum sativum; SP: 
Schizosaccharomyces pombe; SS: Sphingomonas sp.; RE: Rhodococcus erythropolis; RG: Rhodococcus globerulus; XL: Xenopus 
laevis. 
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Homology 
AIF is a highly conserved protein ubiquitously present 
in all primary kingdoms, Bacteria, Archaea and 
Eucaryota. The aif gene is inherited from the last 
universal common ancestor and follows the tree 
topology with the primary radiation of the archaeo-
eukaryotic and bacterial clades. AIF also has a highly 
significant homology with different families of 
oxidoreductases, including NADH oxydases, Ascorbate 
reductases, Glutathione reductases and many NADH-
dependent ferredoxin reductases from Archaea and 
Bacteria to invertebrates and vertebrates.  
Mouse, Rat homology. 
Mutations 
Note: Several polymorphisms have been identified but 
none of them has shown any association with a disease. 
Implicated in 
Various cancers 
Note: Upregulated in cancers (colorectal carcinoma, 
gastric carcinoma, breast carcinoma and hepatocellular 
carcinoma, glioblastoma ). 
AIF expression may play a role in tumor formation and 
could maintain a transformed state of colon cancer cells 
involving mitochondrial complex I function. 
Cell death 
Disease 
AIF has been directly designed as main mediator of cell 
death in ischemic injuries after overproduction of 
reactive oxygen species. Indeed, blocking the 
mitochondrial release of AIF to cytosol and its further 
nuclear translocation provides protection against 
neuronal and cardiomyocites cell death. AIF-deficient 
harlequin mutant mouse presents a significant reduction 
of neuronal cell death in brain trauma and cerebral 
ischemia. A similar protective effect was observed in 
AIF siRNA-treated neurons. 
Degenerative disorders 
Disease 
AIF is involved in several degenerative disorders. The 
elevated production of ROS generated in Amyotrophic 
Lateral Sclerosis, Alzheimer's, or Parkinson diseases 
concludes in the translocation of AIF. Likewise, AIF 
release triggered by calpains and cathepsins was 
observed on in vitro models of Epilepsy and 
Huntington's disease. AIF-mediated cell death is 
involved in the pathogenesis of different retinal 
affections such as retinal detachment, retinitis 
pigmentosa, or in models of retinal hypoxia. Moreovr, 
an increase of AIF expression has been reported in 
patients affected with diabetic retinopathy. 
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